Results 111 to 120 of about 100,863 (292)

Incidence and In‐Hospital Mortality of Ventricular Septal Rupture Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Ventricular septal rupture (VSR) is a rare but devastating complication of acute myocardial infarction (MI), associated with high mortality despite advances in reperfusion therapy. However, contemporary data examining national trends in VSR outcomes and the evolving role of mechanical circulatory support (MCS) in this population ...
Javier Fernandez, Namra Khan, Muni Rubens, Dorsa Majdpour, Masood Azhar, Mukesh Roy, Anshul Saxena, Sandra Chaparro, Javier Jimenez   +8 more
wiley   +1 more source

CaMKII in Regulation of Cell Death During Myocardial Reperfusion Injury. [PDF]

Front Mol Biosci, 2021
Yang Y, Jiang K, Liu X, Qin M, Xiang Y.
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Beclin1 controls caspase-4 inflammsome activation and pyroptosis in mouse myocardial reperfusion-induced microvascular injury. [PDF]

Cell Commun Signal, 2021
Sun W, Lu H, Dong S, Li R, Chu Y, Wang N, Zhao Y, Zhang Y, Wang L, Sun L, Lu D.   +10 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention. [PDF]

Cardiol J, 2023
Muraca I, Pennesi M, Mattesini A, Migliorini A, Carrabba N, Virgili G, Bruscoli F, Demola P, Colombi R, Pontecorboli G, Marchionni N, Di Mario C, Valenti R.   +12 more
europepmc   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies

American Heart Journal Plus
Myocardial ischemia-reperfusion injury (MIRI) remains a critical clinical challenge, often worsening myocardial damage after reperfusion therapy for acute myocardial infarction (AMI).
Yilin Huang, Shuang Li, Yuanlin Zeng, Zeyu Zhang   +3 more
doaj   +1 more source